Cardiovascular Research

Mesenchymal stem cell administration at coronary artery reperfusion in the rat by two delivery routes: a quantitative assessment

Authors: Sharon L Hale|||Wangde Dai|||Joan S Dow|||Robert A Kloner

Affiliations: + Expand

Abstract

Ideally, mesenchymal stem cells (MSC) home to and/or remain at the site of damaged myocardium when administered after myocardial infarction. However, MSC may not remain in the heart, but instead relocate to other areas. We investigated quantitatively the distribution of labeled rat MSC, given by two routes after coronary artery occlusion/reperfusion in rats.

---

Chemical List

Luminescent Agents|||Europium

---

Reference List

Barbash IM, Chouraqui P, Baron J, et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarct myocardium. Feasibility, cell migration, and body distribution. Circulation. 2003;108:863–868.|||Chin BB, Makamoto Y, Bulte JW, Pittenger MF, Wahi R, Kratchman DL. 111In oxine labeled mesenchymal stem cell SPECT after intravenous administration in myocardial infarction. Nuclear Medicine Communications. 2003;24:21149–21154.|||Dai W, Hale SL, Martin BJ, et al. Allogeneic mesenchymal stem cell transplantation in postinfarcted rat myocardium. Short- and long-term effects. Circulation. 2005;112:214–223.|||Dai W, Hale SL, Kloner RA. Role of paracrine action of mesenchymal stem cells in the improvement of left ventricular function after coronary artery occlusion in rats. Regenerative Medicine. 2007;2:63–68.|||Dow JS, Simkhovich BZ, Kedes L, Kloner RA. Washout of transplanted cells from the heart: A potential new hurdle for cell transplantation therapy. Cardiovascular Research. 2005;67:301–307.|||Freyman T, Polin G, Osman H, et al. A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. European Heart Journal. 2006;27:1114–1122.|||Gnecchi M, He H, Noiseux N, et al. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. Federation of American Societies for Experimental Biology Journal. 2006;20:661–669.|||Hare JM, et al. PROVACEL study results. New Orleans, LA: American College of Cardiology Scientific Sessions; 2007. A double-blind, randomized, placebo controlled clinical trial of allogeneic mesenchymal stem cells for the treatment of patients with acute myocardial infarction.|||Hill JM, Dick AJ, Raman VK, et al. Serial cardiac magnetic resonance imaging of injected mesenchymal stem cells. Circulation. 2003;108:1009–1014.|||Jiang WH, Ma AQ, Zhang YM, et al. Migration of intravenously grafted mesenchymal stem cells to injured hearts in rats. Sheng Li Xue Bao. 2005;57:566–572.|||Kawamoto A, Gwon HC, Iwaguro H, et al. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation. 2001;103:634–637.|||Krause U, Harter C, Seckinger A, et al. Intravenous delivery of autologous mesenchymal stem cells limits infarct size and improves left ventricular function in the infarcted porcine heart. Stem Cells and Development. 2007;1:31–37.|||Ma J, Ge J, Zhang S, et al. Time course of myocardial stromal cell-derived factor 1 expression and beneficial effects of intravenously administered bone marrow stem cells in rats with experimental myocardial infarction. Basic Research in Cardiology. 2005;100:217–223.|||Makino S, Fukuda K, Miyoshi S, et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. Journal of Clinical Investigation. 1999;103:697–715.|||Menashe P. Skeletal myoblast transplantation for cardiac repair. Expert Review of Cardiovascular Therapy. 2004;2:21–28.|||Muller-Ehmsen J, Peterson KL, Kedes L, et al. Rebuilding a damaged heart. Long-term survival of transplanted neonatal rat cardiomyocytes after myocardial infarction and effect on cardiac function. Circulation. 2002;105:1721–1726.|||Murry CE, Soonpaa MH, Reinecke H, et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature. 2004;428(6983):664–668.|||Nagaya N, Fujii T, Iwase T, et al. Intravenous administration of mesenchymal stem cells improves cardiac function in rats with acute myocardial infarction though angiogenesis and myogenesis. American Journal of Physiology. 2004;287:H2670–H2676.|||Orlic D, Kajstura J, Chimenti S, Bodine DM, Leri A, Anversa P. Transplanted adult bone marrow cells repair myocardial infarcts in mice. Annals of the New York Academy of Science. 2001;938:221–229.|||Price MJ, Chou CC, Frantzen M, et al. Intravenous mesenchymal stem cell therapy after reperfused acute myocardial infarction improves left ventricular function and alters electrophysiologic properties. International Journal of Cardiology. 2006;111:231–239.|||Terrovitis J, Stuber M, Youssef A, et al. Magnetic resonance imaging overestimates ferumoxide-labeled stem cell survival after transplantation in the heart. Circulation. 2008;117(12):1555–1562.|||Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 2002;105:93–98.|||Vaccaro DE, Reinhardt C, Groman E. A new tracer technology for therapeutic cell tracking. In Vitro Diagnostics Technology. 2006;12:47–53.|||Van der Laarse A, Bloys van Treslong CH, Vliegen HW, Ricciardi L. Relation between ventricular DNA content and number of myocytes and non-myocytes in hearts of normotensive and spontaneously hypertensive rats. Cardiovascular Research. 1987;21(3):223–229.|||Yao M, Dieterle T, Hale SL, et al. Long-term outcome of fetal cell transplantation on postinfarction ventricular remodeling and function. Journal of Molecular and Cellular Cardiology. 2003;35(6):661–670.